为您找到相关结果约500个

你是不是要搜索 期刊Biogen宣布BDCA2单抗BIIB059在皮肤性红斑狼疮和系统性红斑狼疮的2期研究阳性结果 点击跳转

Re-evaluation of human BDCA-2(+) DC during acute sterile skin inflammation

BIIB059, A HUMANIZED MONOCLONAL ANTIBODY TARGETING BDCA2 ON PLASMACYTOID DENDRITIC CELLS (PDC), SHOWSDOSE-RELATED EFFICACY IN THE PHASE 2 LILAC STUDY IN PATIENTS (PTS) WITH ACTIVE CUTANEOUS LUPUS ERYTHEMATOSUS

CD14+ MYELOID CELLS EXPRESS THE PDC MARKERS BDCA-2, BDCA-4, CD123 UPON DIFFERENTIATION IN BOTH HEALTHY

East Pacific Rise Core PS75/059-2: Glacial-to-Deglacial Stratigraphy Revisited

CD303 (BDCA-2) - a potential novel target for therapy in hematologic malignancies

SAFETY, TOLERABILITY, PHARMACOKINETIC AND PHARMACODYNAMIC EFFECT OF BIIB059, A MONOCLONAL ANTIBODY TARGETINGBDCA2 FOLLOWING ADMINISTRATION OF SUBCUTANEOUS SINGLE DOSES IN JAPANESE HEALTHY VOLUNTEERS

BIIB059, A MONOCLONAL ANTIBODY TARGETING BDCA2, SHOWS EVIDENCE OF BIOLOGICAL ACTIVITY AND EARLY CLINICAL

Treatment with BIIB059, a monoclonal antibody targeting BDCA2, improves skin lesions in subjects with

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effect of BIIB059, a Monoclonal Antibody TargetingBDCA2 Following Administration of Subcutaneous Single Doses in Japanese Healthy Volunters

BIIB059, a monoclonal antibody targeting BDCA2, decreases Type I Interferon-related genes transcriptional

Efficacy and Safety Results from a Phase 2, Randomized, Double-Blind Trial of BIIB059, an Anti-BloodDendritic Cell Antigen 2 Antibody, in SLE

Biogen licenses Karyopharm treatment

Biogen resurrects Alzheimer's program

Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of BIIB059, a Monoclonal Antibody TargetingBDCA2 Following Administration of Intravenous and Subcutaneous Single or Multiple Doses in Healthy Volounters

为您找到相关结果约500个

共500条页码: 1/34页15条/页